Prolintane
Catovit · Katovit · Promotil · Villescon · Pondex · 1-(1-phenylpentan-2-yl)pyrrolidine
Last updated
At a glance
Overview
Prolintane is a discontinued European pharmaceutical (Katovit, Catovit) that built a quiet second life as a cult NDRI stimulant in the nootropic and pre-training community. Mechanistically it sits much closer to methylphenidate or cocaine than to racetams or modafinil — low-nanomolar blockade of DAT and NET, with a clean dose-dependent arousal, focus, and motivation profile that experienced stimulant rotators reach for specifically because it feels distinct from amphetamines.
The appeal is the texture: ~4–6 hours of noradrenergic drive and dopaminergic warmth without the peripheral edge of ephedrine or the appetite-flattening burnout of lisdexamfetamine. Physique-focused users deploy it as a non-daily pre-workout on heavy lift days, looksmaxxers and desk-bound users run 10–20 mg on waking for sustained focus blocks, and cutting protocols layer it 2–3×/week for fasted-cardio output. The clinical-era dose range was 10–30 mg orally; community practice extends to 30–50 mg, with anything above that sitting squarely in recreational territory.
"Prolintane displays potent inhibition of human dopamine and norepinephrine transporters in the low nanomolar range, producing dose-dependent psychostimulant and sympathomimetic effects in clinical dose ranges." — Kastner et al., J Biol Chem (2025)
The catch — and the reason the protocol matters more than the molecule — is that DAT blockade this clean comes with real abuse liability and fast tolerance when dosed daily. The sections below cover documented prolintane dose ladders, AM-only timing windows, cycle length, stack pairings with L-tyrosine and magnesium, the diphenhydramine interaction to avoid, and the most common protocol mistakes reported in the literature.
How Prolintane works
Prolintane is a norepinephrine–dopamine reuptake inhibitor (NDRI) of the phenylalkylpyrrolidine class, structurally a parent scaffold to pyrovalerone and α-PVP but functionally closer to methylphenidate than to amphetamine-type releasers. The compound acts primarily through transporter blockade in catecholaminergic circuits, with downstream effects on cortical arousal, motivational drive, sympathetic tone, and sleep architecture. For the physique-focused and looksmaxxing reader, the relevant outputs are pre-training arousal, sustained cognitive output during cuts, and an appetite-suppressing noradrenergic edge — all delivered without the harsh peripheral profile of ephedrine or the daily-dose entanglement of prescribed amphetamines.
DAT and NET Blockade#
The defining mechanism is potent, low-nanomolar inhibition of the human dopamine transporter (DAT) and norepinephrine transporter (NET). Blocking reuptake elevates synaptic dopamine and norepinephrine in mesolimbic and prefrontal circuits, which translates behaviourally into the focus, motivation, and locomotor activation that define the clinical and recreational profile.
"Prolintane displays potent inhibition of human dopamine and norepinephrine transporters in the low nanomolar range, producing dose-dependent psychostimulant and sympathomimetic effects in clinical dose ranges." — Kastner N, Islam MN, Dybek M, et al. Journal of Biological Chemistry, 2025
For physique-focused users, this is the mechanism behind the pre-training arousal lift and the appetite suppression that makes the compound useful as an episodic adjunct on a cut.
Striatal Dopamine Elevation and Reward Signal#
Beyond transporter occupancy in vitro, in vivo work confirms that prolintane meaningfully elevates extracellular dopamine in the striatum and produces a cocaine-adjacent interoceptive cue in drug-discrimination procedures.
"A single administration of prolintane resulted in dose-dependent locomotor activation and robust increases in striatal extracellular dopamine levels, as well as partial substitution for cocaine in drug discrimination procedures." — Lee W, Lee JW, Kim JM, et al. Neuropharmacology, 2022
The practical takeaway is that the reward signal is real and measurable, not just noradrenergic arousal. This is why community protocols cap frequency at 2–3 dosing days per week — daily dosing recruits the reinforcement axis far more aggressively than caffeine or modafinil, and DAT-mediated tolerance develops within days.
Sympathomimetic Peripheral Tone#
NET blockade in the periphery produces the predictable stimulant-class cardiovascular signature: modest pressor effect, elevated heart rate, mydriasis, sweating, and bruxism. This is the same mechanistic family as methylphenidate, and the same monitoring logic applies — resting HR and BP tracked with a home cuff during any dosing block, and a hard contraindication against stacking with yohimbine, clenbuterol, ephedrine, or DMAA, which all load the same axis.
REM Suppression and Sleep Architecture#
Prolintane shortens REM sleep and extends sleep latency in a pattern shared with other sympathomimetic stimulants. This is the mechanistic basis for the AM-only dosing window and the 14:00 cutoff documented in community protocols.
"Prolintane significantly reduced the duration of REM sleep and increased sleep latency, in a manner similar to other sympathomimetic stimulants." — Nicholson AN, Stone BM. British Journal of Clinical Pharmacology, 1980
Recovery-oriented users on AAS cycles should weight this carefully — REM debt undermines the same recovery axis the cycle is meant to support, which is why episodic rather than daily dosing is the only defensible structure.
Anticholinergic Interaction Risk#
A clinically meaningful and mechanistically distinct interaction emerges when prolintane is combined with diphenhydramine or other first-generation antihistamines. The pairing has produced complex visual hallucinations at otherwise unremarkable doses, attributed to potentiated central dopaminergic activity layered on anticholinergic blockade.
"Use of prolintane in combination with diphenhydramine resulted in the appearance of complex visual hallucinations, indicating a clinically relevant interaction between these two agents." — Payá B, Guisado JA, Vaz FJ, Crespo-Facorro B. Pharmacopsychiatry, 2002
For lifters who reach for diphenhydramine as an evening sleep aid, this is a hard avoid on dosing days — magnesium glycinate or a non-anticholinergic alternative is the cleaner pairing.
Why the Pyrrolidine Ring Matters#
The tertiary-amine pyrrolidine ring is what separates prolintane from the classical amphetamine releasers. It confers high DAT affinity comparable to pyrovalerone-class analogs while keeping the compound predominantly a reuptake inhibitor rather than a substrate-type releaser. Practically, this means a smoother arousal curve than amphetamine, less of the appetite-annihilating edge, and a duration profile (≈4–6 h behavioral) that fits cleanly into a single morning dose without bleeding into the evening sleep window — provided the protocol respects the AM cutoff.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 10–20 mg | As needed | Documented entry-level range |
| Mid | 20–30 mg | As needed | Most commonly studied range |
| High | 30–50 mg | As needed | Episodic, non-daily dosing — typically 2–3 days per week with a hard AM-only window (14:00 cutoff) to protect REM sleep. Daily dosing produces fast DAT tolerance and pulls the compound into compulsive territory. |
Cycle length & outcomes
Documented cycle
2–6 weeks
Plateau after
6 wks
Cycle Structure & Onset#
Prolintane is not a "cycle" compound in the AAS sense — it's an episodic stimulant, and the protocol architecture reflects that. The two non-negotiables are non-daily dosing and a hard AM-only window, both driven by the pharmacology: rapid DAT-mediated tolerance on daily use, and a documented suppression of REM sleep that compounds across consecutive nights.
"Prolintane significantly reduced the duration of REM sleep and increased sleep latency, in a manner similar to other sympathomimetic stimulants." — Nicholson & Stone, Br J Clin Pharmacol (1980)
Onset is fast: oral administration produces noticeable arousal within 30–60 minutes, peak effect around the 1.5-hour mark, and a working window of roughly 4–6 hours of stimulation before the curve falls. A residual "tail" of mild mood elevation and sympathetic tone can extend into the evening at heavier doses — which is exactly why the 14:00 cutoff is enforced even though the acute effect is gone by then.
There is no loading phase and no taper. The compound is either dosed or it isn't.
Dose Ladder by Goal#
| Goal | Cycle Length | Per-Dose | Frequency |
|---|---|---|---|
| Cognitive / focus (light) | 2–4 weeks | 10–20mg AM | 2–3×/week |
| Pre-training arousal | 4–6 weeks | 20–30mg, 45–60min pre-session | 2–3×/week, heavy days only |
| Fat-loss adjunct (pre-cardio) | 4–6 weeks | 20mg pre-fasted-cardio | 2–3×/week |
| Mood/drive on a deep cut | 2–4 weeks | 10–20mg AM | 1–2×/week |
| Acute deadline push | Single use | 20–30mg AM | Once per 2–4 weeks |
Ceiling. The community curve runs 2–3× the original Katovit-era clinical label (10–30mg, 1–3×/day). Doses above 50mg push into the range where the abuse-liability signal demonstrated in rodent self-administration and cocaine-discrimination studies starts to show up clinically — pronounced reward, post-dose cravings, and a meaningfully different risk profile.
"A single administration of prolintane resulted in dose-dependent locomotor activation and robust increases in striatal extracellular dopamine levels, as well as partial substitution for cocaine in drug discrimination procedures." — Lee et al., Neuropharmacology (2022)
Cycle Length & Washout#
A defined block — 2–6 weeks of episodic dosing, then a 2–4 week washout — keeps DAT sensitivity intact and prevents the slide into compulsive daily use that has been documented in case reports of non-medical use.
"Prolintane detected by GC-MS in a sample obtained from a patient who admitted to nonmedical, repeated use suggests its easy access and the potential for domestic and recreational misuse outside prescription settings." — Kyle & Daley, J Anal Toxicol (2007)
The 6-week ceiling isn't a pharmacokinetic limit — it's a behavioral one. By week six of any stimulant block, tolerance has eroded the cognitive return, and the temptation to compensate with daily dosing or dose escalation is where users get into trouble.
Onset Expectations by Use Case#
- Focus / cognitive work: noticeable from the first dose. There is no build-up phase — the NDRI mechanism produces an acute effect, not a cumulative one.
- Pre-training arousal: first session typically the best. Subsequent sessions in the same week should be spaced to avoid back-to-back dosing.
- Fat-loss adjunct: appetite suppression and session-output benefits are immediate; the fat-loss contribution is modest (~0.1 lb/week attributable) and only meaningful inside a structured deficit.
- Mood/drive support on a cut: felt the day of dosing. Prolintane is not a replacement for fixing estradiol, calories, or sleep — it's a top-up on days where those are already managed.
Monitoring#
No hormonal bloodwork applies — prolintane has no HPTA, androgen, estrogen, or aromatase activity. There is no PCT requirement. Monitoring is cardiovascular:
- Resting HR and BP with a home cuff, weekly during an active dosing block. A persistent shift of +10mmHg systolic or +10bpm resting between dosing days is the threshold to pull back.
- Standard CMP and lipid panel quarterly if prolintane is layered onto an AAS cycle, since the underlying cycle is doing the heavy lifting on those markers.
- Subjective sleep quality is the second canary. REM suppression compounds across nights; any drift into 5-hour nights or fragmented sleep is the signal to either tighten the AM cutoff or drop the dosing frequency.
Stack Notes#
- L-tyrosine 500–1000mg the evening before and the morning of dosing — keeps catecholamine substrate available across a 2–3×/week schedule.
- Magnesium glycinate in the evening on dosing days, to soften residual sympathetic tone and protect sleep architecture.
- Caffeine at 50–100mg only if tolerance to caffeine is low. Doubling up on strong stimulants inherits the cardiac load without a proportional cognitive return.
- Avoid: diphenhydramine (documented hallucination interaction per Payá et al., 2002), MAOIs/RIMAs, yohimbine, clenbuterol, ephedrine, DMAA, and any other full-dose stimulant stacked on top.
Results from a well-structured prolintane block are felt acutely on each dosing day rather than accumulating over weeks. The compound rewards restraint — the users who run it episodically inside a defined 2–6 week block and walk away cleanly are the ones who keep it as a useful tool in rotation rather than burning out the DAT response inside a month.
Body Transformation Preview
Lean Mass Gain
0.0 lbs
0.0–0.0 lbs range
Fat Loss
0.4 lbs
0.3–0.5 lbs range
Fat Loss by Week
Risks & mistakes
Common (most users)#
Prolintane is a clean NDRI with a predictable sympathomimetic profile — the common effects are the catecholamine load itself, and most resolve with dose, timing, and stack adjustments.
- Elevated heart rate and blood pressure — expected at any clinical dose. Resting HR typically climbs 10–20 bpm at 20–30mg. Mitigation: keep doses ≤30mg in the early cycle, monitor with a home cuff on dosing days, and avoid co-administration with caffeine above 100mg or any other sympathomimetic.
- Insomnia and suppressed REM — Nicholson & Stone documented dose-dependent REM reduction and prolonged sleep latency similar to other sympathomimetic stimulants. Mitigation: hard 14:00 cutoff, magnesium glycinate 300–400mg in the evening, and non-daily dosing (2–3×/week maximum).
"Prolintane significantly reduced the duration of REM sleep and increased sleep latency, in a manner similar to other sympathomimetic stimulants." — Nicholson & Stone, Br J Clin Pharmacol (1980)
- Appetite suppression — useful on a cut, problematic in a recomp or lean-gain block. Mitigation: front-load calories before dosing, schedule the first solid meal regardless of hunger signal.
- Bruxism and jaw clench — typical of any DAT-active stimulant. Mitigation: magnesium, hydration, and a sugar-free gum or a night guard if it persists into the evening.
- Mydriasis, mild sweating, dry mouth — expected and benign. Hydrate and supplement electrolytes on dosing days.
- Post-dose dip and irritability — the catecholamine "tail-off" 5–7h after dosing. Mitigation: L-tyrosine 500–1000mg the evening before and morning of dosing keeps substrate available; avoid layering a second dose to chase the fade.
Uncommon (dose-dependent or individual)#
These show up above the 30mg threshold or in users layering prolintane with other stimulants.
- Anxiety, agitation, racing thoughts — characteristic of NDRI overshoot. Back off to 10–20mg and extend the gap between dosing days. If anxiety persists at low doses, prolintane is the wrong stimulant for that neurochemistry.
- Palpitations or ectopic beats — pull the dose immediately and reassess BP/HR. A baseline ECG is reasonable for anyone running prolintane on top of an AAS cycle.
- Cravings and compulsive re-dosing — Lee et al. (2022) showed partial cocaine substitution in drug-discrimination procedures and robust striatal dopamine release, which is the mechanistic basis for the abuse-liability signal.
"A single administration of prolintane resulted in dose-dependent locomotor activation and robust increases in striatal extracellular dopamine levels, as well as partial substitution for cocaine in drug discrimination procedures." — Lee et al., Neuropharmacology (2022)
Mitigation: hard frequency cap (≤3 days/week), hard cycle ceiling (4–6 weeks then washout), oral-only route. Insufflation sharpens the reward signal and is the fastest route into compulsive territory.
- Persistent hypertension across a dosing block — check resting BP weekly. Sustained systolic >140 or diastolic >90 on non-dosing days is the signal to stop the cycle entirely, not just lower the dose.
- Mood crash on washout — more common after 4+ weeks of frequent dosing. Tyrosine, sunlight, training, and time. SSRIs are not a fix for stimulant tail-off and should not be reached for here.
Rare but serious#
Low-incidence but clinically significant — these are the signals to stop and not restart.
- Complex visual hallucinations on a prolintane + diphenhydramine combination — documented at therapeutic doses. Stop both agents; the interaction is clinically relevant and reproducible.
"Use of prolintane in combination with diphenhydramine resulted in the appearance of complex visual hallucinations, indicating a clinically relevant interaction between these two agents." — Payá et al., Pharmacopsychiatry (2002)
- Seizure — extrapolated risk from the broader pyrrolidine-stimulant class, particularly at high or insufflated doses. Any seizure activity ends the cycle permanently.
- Hypertensive crisis — the mechanistically obvious risk if prolintane is layered with an MAOI or a high pressor load (yohimbine + clenbuterol + AAS). Severe headache, visual disturbance, chest pain — emergency presentation.
- Stimulant-induced psychosis — described in case reports of heavy recreational use of pyrrolidine stimulants. Paranoia, persistent hallucinations, or thought disorganization is a hard stop.
- Arrhythmia or ischemic chest pain — discontinue immediately and get a cardiology workup before any future stimulant use of any class.
Hard contraindications#
These lines do not get crossed.
- MAOIs (including selegiline, moclobemide, phenelzine) — hypertensive crisis risk. Mechanistically obvious for any NDRI.
- Diphenhydramine and other strongly anticholinergic first-generation antihistamines — documented hallucination interaction in the published literature.
- Untreated hypertension, structural heart disease, arrhythmia, or pheochromocytoma — the cardiovascular load is non-negotiable and will be additive to any pre-existing pathology.
- Concurrent full-dose stimulants — amphetamines, methylphenidate, cocaine, MDMA, DMAA, high-dose ephedrine. Cardiac and dopaminergic load compounds without proportional cognitive benefit.
- Pregnancy — no safety data, no rationale, no exceptions.
- In-competition athletes — WADA-prohibited in-competition and detected by standard stimulant screening panels.
- Documented stimulant use disorder or active cocaine/amphetamine dependence — the cocaine-discriminative profile makes prolintane the wrong tool for this population, full stop.
Gender and PCT considerations#
Prolintane has no androgen, estrogen, progestin, or HPTA activity. No virilization risk, no aromatase considerations, no menstrual-cycle effects beyond the appetite and sleep changes common to any stimulant. PCT is not required and not relevant — prolintane sits entirely outside the steroid pharmacology axis. The only sex-neutral monitoring that matters is cardiovascular: home BP/HR on dosing days, and a standard lipid/CMP panel quarterly if prolintane is being layered onto an AAS cycle where lipids and pressure are already moving.
FAQ — Prolintane
Research & citations
5 studies cited on this page.
Conclusion
Prolintane stands out as a uniquely clean, short-duration NDRI — offering rapid-onset focus, motivation, and drive that rivals methylphenidate without the harsh amphetamine edge or appetite suppression. Its favorable behavioral profile and manageable cardiovascular footprint make it a strong episodic tool in the nootropic and pre-training rotation when protocols are respected.
Key takeaways:
- Typical oral dose: 10–30 mg per session, AM-only with a strict 14:00 cutoff to protect sleep
- Non-daily, episodic use (2–3×/week, 4–6 week block) keeps tolerance and dependency risk low
- Stacking support: L-tyrosine (500–1000 mg) evening before and morning of dosing; magnesium glycinate at night for sleep protection
- Avoid any co-administration with diphenhydramine (hallucination risk), MAOIs, or full-dose stimulants
- Best suited for protocol-driven focus, acute motivational pushes, or clean pre-workout arousal — not for daily baseline elevation
Within research protocols emphasizing tight cycling and smart stacking, prolintane remains a distinct and effective addition for focus and arousal in the stimulant toolkit.